Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

The link between inflammatory disease and patterns of leukocyte recruitment.

Newman W, Mirabelli CK.

Expert Opin Investig Drugs. 1998 Jan;7(1):19-25.

PMID:
15991916
2.

Lipid membrane permeability of 2'-modified derivatives of phosphorothioate oligonucleotides.

Hughes JA, Bennett CF, Cook PD, Guinosso CJ, Mirabelli CK, Juliano RL.

J Pharm Sci. 1994 Apr;83(4):597-600.

PMID:
8046622
3.

Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression.

Perlaky L, Saijo Y, Busch RK, Bennett CF, Mirabelli CK, Crooke ST, Busch H.

Anticancer Drug Des. 1993 Feb;8(1):3-14.

PMID:
8476501
4.
5.

Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.

Bennett CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK.

Mol Pharmacol. 1992 Jun;41(6):1023-33.

PMID:
1352033
6.

Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively.

Tan KB, Dorman TE, Falls KM, Chung TD, Mirabelli CK, Crooke ST, Mao J.

Cancer Res. 1992 Jan 1;52(1):231-4.

7.

In vitro and in vivo pharmacologic activities of antisense oligonucleotides.

Mirabelli CK, Bennett CF, Anderson K, Crooke ST.

Anticancer Drug Des. 1991 Dec;6(6):647-61. Review.

PMID:
1663361
8.
9.
10.

Antiarthritic and suppressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents.

Badger AM, Schwartz DA, Picker DH, Dorman JW, Bradley FC, Cheeseman EN, DiMartino MJ, Hanna N, Mirabelli CK.

J Med Chem. 1990 Nov;33(11):2963-70.

PMID:
2146392
11.

Gold(I) efflux from auranofin-treated red blood cells. Evidence for a glutathione-gold-albumin metabolite.

Shaw CF 3rd, Isab AA, Coffer MT, Mirabelli CK.

Biochem Pharmacol. 1990 Sep 15;40(6):1227-34.

PMID:
2403377
12.
13.

Induction of non-specific suppressor cells in normal Lewis rats by a novel azaspirane SK&F 105685.

Badger AM, King AG, Talmadge JE, Schwartz DA, Picker DH, Mirabelli CK, Hanna N.

J Autoimmun. 1990 Aug;3(4):485-500.

PMID:
2145847
14.

Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.

Woessner RD, Chung TD, Hofmann GA, Mattern MR, Mirabelli CK, Drake FH, Johnson RK.

Cancer Res. 1990 May 15;50(10):2901-8.

15.

Cytotoxicity and antitumor activity of some tetrahedral bis(diphosphino)gold(I) chelates.

Berners-Price SJ, Girard GR, Hill DT, Sutton BM, Jarrett PS, Faucette LF, Johnson RK, Mirabelli CK, Sadler PJ.

J Med Chem. 1990 May;33(5):1386-92.

PMID:
2329559
17.

Mechanism of inhibition of rat liver mitochondrial respiration by oxmetidine, an H2-receptor antagonist.

Hoke GD, Cheng HY, Mirabelli CK, Rush GF.

J Pharmacol Exp Ther. 1990 Mar;252(3):908-14.

PMID:
1969477
18.

Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes.

Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK.

Proc Natl Acad Sci U S A. 1989 Dec;86(23):9431-5.

19.

Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK.

Biochemistry. 1989 Oct 3;28(20):8154-60.

PMID:
2557897
20.

In vivo and in vitro cardiotoxicity of a gold-containing antineoplastic drug candidate in the rabbit.

Hoke GD, Macia RA, Meunier PC, Bugelski PJ, Mirabelli CK, Rush GF, Matthews WD.

Toxicol Appl Pharmacol. 1989 Sep 1;100(2):293-306.

PMID:
2781559
21.

Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells.

Mattern MR, Tan KB, Zimmerman JP, Mong SM, Bartus JO, Hofmann GA, Drake FH, Johnson RK, Crooke ST, Mirabelli CK.

Anticancer Drug Des. 1989 Aug;4(2):107-24.

PMID:
2478139
22.

Multiple (alpha-NH-ubiquitin)protein endoproteases in cells.

Jonnalagadda S, Butt TR, Monia BP, Mirabelli CK, Gotlib L, Ecker DJ, Crooke ST.

J Biol Chem. 1989 Jun 25;264(18):10637-42.

23.

Mechanism of toxicity of an experimental bidentate phosphine gold complexed antineoplastic agent in isolated rat hepatocytes.

Smith PF, Hoke GD, Alberts DW, Bugelski PJ, Lupo S, Mirabelli CK, Rush GF.

J Pharmacol Exp Ther. 1989 Jun;249(3):944-50.

PMID:
2732955
24.
26.

In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.

Drake FH, Hofmann GA, Mong SM, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR, Mirabelli CK.

Cancer Res. 1989 May 15;49(10):2578-83.

27.

Pharmacological activities of spirogermanium and other structurally related azaspiranes: effects on tumor cell and macrophage functions.

Mirabelli CK, Badger AM, Sung CP, Hillegass L, Sung CM, Johnson RK, Picker D, Schwartz D, Dorman J, Martellucci S.

Anticancer Drug Des. 1989 Mar;3(4):231-42.

PMID:
2930625
28.

Inhibition of animal models of autoimmune disease and the induction of non-specific suppressor cells by SK&F 105685 and related azaspiranes.

Badger AM, Dimartino MJ, Talmadge JE, Picker DH, Schwartz DA, Dorman JW, Mirabelli CK, Hanna N.

Int J Immunopharmacol. 1989;11(7):839-46.

PMID:
2532178
29.

Altered expression and transcription of the topoisomerase II gene in nitrogen mustard-resistant human cells.

Tan KB, Per SR, Boyce RA, Mirabelli CK, Crooke ST.

Biochem Pharmacol. 1988 Nov 15;37(22):4413-6. No abstract available. Erratum in: Biochem Pharmacol 1989 May 1;38(9):1541.

PMID:
2848529
30.

A murine model to evaluate the ability of in vitro clonogenic assays to predict the response to tumors in vivo.

Mirabelli CK, Sung CM, McCabe FL, Faucette LF, Crooke ST, Johnson RK.

Cancer Res. 1988 Oct 1;48(19):5447-54.

31.

Mechanism of alterations in isolated rat liver mitochondrial function induced by gold complexes of bidentate phosphines.

Hoke GD, Rush GF, Bossard GF, McArdle JV, Jensen BD, Mirabelli CK.

J Biol Chem. 1988 Aug 15;263(23):11203-10.

32.

Antimicrobial and anticancer activity of tetrahedral, chelated, diphosphine silver(I) complexes: comparison with copper and gold.

Berners-Price SJ, Johnson RK, Giovenella AJ, Faucette LF, Mirabelli CK, Sadler PJ.

J Inorg Biochem. 1988 Aug;33(4):285-95.

PMID:
3139831
33.

Immunomodulatory activity and non-specific suppressor cell generation by spirogermanium in murine and rat models of cell-mediated immunity.

Badger AM, DiMartino MJ, Swift BA, Mirabelli CK.

Immunopharmacology. 1988 Jul-Aug;16(1):33-43.

PMID:
2971635
34.
35.

Tumorigenicity of the cyc- variant of the S49 murine lymphoma deficient in the Gs-alpha subunit of adenylate cyclase.

Stadel JM, Johnson RK, Mirabelli CK, Powers DA, Sung CM, Faucette LF, McCabe FL, Crooke ST.

Cancer Res. 1988 Feb 1;48(3):641-4.

36.

Expression and accurate processing of yeast penta-ubiquitin in Escherichia coli.

Jonnalagadda S, Butt TR, Marsh J, Sternberg EJ, Mirabelli CK, Ecker DJ, Crooke ST.

J Biol Chem. 1987 Dec 25;262(36):17750-6.

37.

Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.

Mirabelli CK, Hill DT, Faucette LF, McCabe FL, Girard GR, Bryan DB, Sutton BM, Bartus JO, Crooke ST, Johnson RK.

J Med Chem. 1987 Dec;30(12):2181-90.

PMID:
3681888
38.

The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes. II. Triethylphosphine gold chloride-induced alterations in mitochondrial function.

Rush GF, Smith PF, Hoke GD, Alberts DW, Snyder RM, Mirabelli CK.

Toxicol Appl Pharmacol. 1987 Sep 30;90(3):391-400.

PMID:
3660409
39.

The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes. I. Characterization of triethylphosphine gold chloride-induced biochemical and morphological changes in isolated hepatocytes.

Rush GF, Smith PF, Alberts DW, Mirabelli CK, Snyder RM, Crooke ST, Sowinski J, Jones HB, Bugelski PJ.

Toxicol Appl Pharmacol. 1987 Sep 30;90(3):377-90.

PMID:
3660408
40.

Effect of auranofin and other gold complexes on the activity of phospholipase C.

Snyder RM, Mirabelli CK, Clark MA, Ziegler JT, Crooke ST.

Mol Pharmacol. 1987 Sep;32(3):437-42.

PMID:
3118179
41.

The cellular pharmacology of auranofin.

Snyder RM, Mirabelli CK, Crooke ST.

Semin Arthritis Rheum. 1987 Aug;17(1):71-80. Review. No abstract available.

PMID:
3306933
42.

Thiol competition for Et3PAuS-albumin: a nonenzymatic mechanism for Et3PO formation.

Coffer MT, Shaw CF 3rd, Hormann AL, Mirabelli CK, Crooke ST.

J Inorg Biochem. 1987 Jul;30(3):177-87.

PMID:
3655788
43.

Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.

Per SR, Mattern MR, Mirabelli CK, Drake FH, Johnson RK, Crooke ST.

Mol Pharmacol. 1987 Jul;32(1):17-25.

PMID:
3037302
44.

Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells.

Mattern MR, Mong SM, Bartus HF, Mirabelli CK, Crooke ST, Johnson RK.

Cancer Res. 1987 Apr 1;47(7):1793-8.

45.

Cellular interactions of auranofin and a related gold complex with RAW 264.7 macrophages.

Snyder RM, Mirabelli CK, Crooke ST.

Biochem Pharmacol. 1987 Mar 1;36(5):647-54.

PMID:
3827949
46.

Induction of metallothionein is correlated with resistance to auranofin, a gold compound, in Chinese hamster ovary cells.

Monia BP, Butt TR, Mirabelli CK, Ecker DJ, Sternberg E, Crooke ST.

Mol Pharmacol. 1987 Jan;31(1):21-6.

PMID:
3807890
47.

Suppressor cell induction by the anticancer drug spirogermanium.

Badger AM, DiMartino MJ, Schmitt TC, Swift BA, Mirabelli CK.

Int J Immunopharmacol. 1987;9(5):621-30.

PMID:
2957334
48.

In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride.

Berners-Price SJ, Mirabelli CK, Johnson RK, Mattern MR, McCabe FL, Faucette LF, Sung CM, Mong SM, Sadler PJ, Crooke ST.

Cancer Res. 1986 Nov;46(11):5486-93.

49.

Cellular pharmacology of mu-[1,2-bis(diphenylphosphino)ethane]bis[(1-thio-beta-D-gluco pyranosato-S)gold(I)]: a novel antitumor agent.

Mirabelli CK, Jensen BD, Mattern MR, Sung CM, Mong SM, Hill DT, Dean SW, Schein PS, Johnson RK, Crooke ST.

Anticancer Drug Des. 1986 Nov;1(3):223-34.

PMID:
3450295
50.

Cellular and molecular pharmacology of auranofin and related gold complexes.

Crooke ST, Snyder RM, Butt TR, Ecker DJ, Allaudeen HS, Monia B, Mirabelli CK.

Biochem Pharmacol. 1986 Oct 15;35(20):3423-31. Review. No abstract available.

PMID:
3533080

Supplemental Content

Loading ...
Support Center